<DOC>
	<DOCNO>NCT00116285</DOCNO>
	<brief_summary>The purpose study evaluate residual allergenicity modify ragweed pollen Ragweed MATA MPL ( modify pollen allergen tyrosine adsorbate + Monophosphoryl Lipid A ) skin prick test . This do comparison wheal response skin prick test different concentration aqueous native allergen , modify allergen , modify tyrosine adsorb allergen , Ragweed MATA MPL .</brief_summary>
	<brief_title>Assessment Residual Allergenicity Ragweed Pollen Allergoid With Monophosphoryl Lipid A ( MPL ) Using Skin Prick Testing</brief_title>
	<detailed_description>Ragweed MATA MPL develop provide pre-seasonal specific immunotherapy patient prove type I hypersensitivity ragweed pollen . MPL ( Monophosphoryl Lipid A ) , purify , detoxify glycolipid derive cell wall Salmonella minnesota , include product formulation adjuvant increase immunogenic effect product enhance switch allergen-specific TH2 TH1-like profile . The ragweed pollen extract modify glutaraldehyde produce active ingredient , allergoid . This modification reduce reactivity extract IgE antibody , thus reduce risk side effect . However , simultaneous reduction important immunological property , IgG T cell reactivity see . The purpose study assess residual allergenicity modify ragweed pollen Ragweed MATA MPL use skin prick testing .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Hypersensitivity , Immediate</mesh_term>
	<mesh_term>Monophosphoryl lipid A</mesh_term>
	<criteria>If volunteer female childbearing potential , must demonstrate negative urine pregnancy test agree remain abstinent use effective method birth control Positive skin prick test ragweed pollen allergen extract Positive skin prick test positive histamine control Negative skin prick test negative control ; redness , wheal acceptable The subject must demonstrate specific IgE ragweed class &gt; = 2 . The subject must clinically acceptable result screen procedure include blood pressure ( BP ) , heart rate ( HR ) , electrocardiogram ( ECG ) , physical examination , medical history , hematology , biochemistry , infection screen ( hepatitis B antigen , hepatitis C antibody , HIV ) , urine pregnancy test , urinalysis , drug abuse screen panel saliva alcohol test History presence acute subacute atopic dermatitis , chronic dermatitis , urticaria factitia , urticaria due physical/chemical influence skin condition might interfere interpretation skin prick test result Visual inspection forearm indicate potential problem conduct interpretation skin prick test ; forearm must available test Subject asthma low respiratory tract condition History presence diabetes , cancer clinically significant cardiac , metabolic , renal , hepatic , gastrointestinal , dermatologic , venereal , hematologic , neurologic psychiatric disease disorder Any clinically significant abnormal laboratory value Visit 1 Clinically relevant sensitivity follow common perennial seasonal allergen : house dust mite , mold , epithelium , grass pollen mix , plantain , orache , nettle , mugwort , bermuda grass Clinically relevant symptom due IgEmediated allergy screen inclusion treatment period Secondary alteration affect organ History autoimmune disease rheumatoid diseases Medical condition prohibits use adrenaline Disorder tyrosine metabolism Diseases interfere immune response receive medication could influence result study Subject acute chronic infection History anaphylaxis Subjects determine Investigator medical condition could jeopardize health prejudice result History hypersensitivity excipients study medication History immunotherapy ragweed allergen extract Current therapy ÃŸblockers Currently receive antiallergy medication drug antihistaminic activity Subject positive drug abuse screen Visit 1 Subject participate clinical trial take investigational drug within last 30 day Subject communicate reliably Investigator deem uncooperative noncompliant Females pregnant , breastfeeding , refuse use reliable method birth control Subject receive treatment preparation contain MPL past 12 month Use prohibit medication inadequate washout period prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>allergy</keyword>
	<keyword>skin prick test</keyword>
	<keyword>allergoid</keyword>
	<keyword>allergenicity</keyword>
	<keyword>specific immunotherapy</keyword>
</DOC>